Literature DB >> 18324356

Dissociated invasively growing cancer cells with NF-kappaB/p65 positivity after radiotherapy: a new marker for worse clinical outcome in rectal cancer? Preliminary data.

Rene Voboril1, Jana Voborilova, Vlasta Rychterova, Tomas Jirasek, Josef Dvorak.   

Abstract

Objectives Nuclear factor-kappaB (NF-kappaB), especially p65 subunit, seems to be associated with origin and progression of cancer. The aim of the study was to determine expression of NF-kappaB/p65 in rectal cancer patients before and after radiotherapy as well as to assess the relationship between NF-kappaB/p65 expression, other tumor characteristics, and disease progression. Further aim was to evaluate whether expression of NF-kappaB/p65 in tumor tissue may serve as a predictive marker of patient outcome. Patients and methods Twenty-five patients with rectal cancer undergoing pre-operative radiotherapy were included in the study. Unirradiated rectal cancer specimens were obtained from diagnostic colonoscopy. Irradiated rectal cancer specimens were obtained from surgically removed part of the rectum with the tumor. NF-kappaB/p65 expression was determined by immunohistochemistry. Results Cytoplasmic positivity in cancer cells and nuclear positivity in lymphocytes were detected. In post-radiotherapy specimens single tumor cells or small clones of them deeply infiltrating the wall of the rectum, that were characterized by high NF-kappaB/p65 expression, were found. Patients with presence of these cells in post-radiotherapy specimens have worse clinical outcome in terms of overall survival and disease-free interval. Conclusion While the NF-kappaB/p65 positive staining of the epithelial cells did not have any clinical implications in this study, it may be of clinical significance in the future. Residual invasively growing cancer cells with high NF-kappaB/p65 positivity found in specimens after radiotherapy and surgery may be used to find what patients have a worse outcome. Thus, patients being at risk of cancer progression and requiring more aggressive anti-cancer therapy may be identified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324356     DOI: 10.1007/s10585-008-9155-5

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  20 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

3.  Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.

Authors:  Joakim Folkesson; Helgi Birgisson; Lars Pahlman; Bjorn Cedermark; Bengt Glimelius; Ulf Gunnarsson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

4.  Constitutive NF-kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis.

Authors:  R Voboril; J Weberova-Voborilova
Journal:  Neoplasma       Date:  2006       Impact factor: 2.575

5.  Activation of nuclear factor kappa B in Crohn's disease.

Authors:  R D Ellis; J R Goodlad; G A Limb; J J Powell; R P Thompson; N A Punchard
Journal:  Inflamm Res       Date:  1998-11       Impact factor: 4.575

Review 6.  The NF-kappa B and I kappa B proteins: new discoveries and insights.

Authors:  A S Baldwin
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 7.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses.

Authors:  S Ghosh; M J May; E B Kopp
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

8.  Protein expression of NF-kappaB in human colorectal adenocarcinoma.

Authors:  Sofia Evertsson; Xioa-Feng Sun
Journal:  Int J Mol Med       Date:  2002-11       Impact factor: 4.101

9.  Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis.

Authors:  Hong-Gang Yu; Liang-Liang Yu; Yanning Yang; He-Sheng Luo; Jie-Ping Yu; Juris J Meier; Henning Schrader; Andreas Bastian; Wolfgang E Schmidt; Frank Schmitz
Journal:  Oncology       Date:  2003       Impact factor: 2.935

10.  Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines.

Authors:  S Miyamoto; P J Chiao; I M Verma
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

View more
  4 in total

1.  Inflammation and cancer.

Authors:  Noemí Eiró; Francisco J Vizoso
Journal:  World J Gastrointest Surg       Date:  2012-03-27

Review 2.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

3.  Prognostic value of c-FLIPL/s, HIF-1α, and NF-κβ in stage II and III rectal cancer.

Authors:  Anna Novell; Montserrat Martínez-Alonso; Moises Mira; Jordi Tarragona; Antonieta Salud; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2014-04-08       Impact factor: 4.064

Review 4.  NF-κB Expression and Outcomes in Solid Tumors: A Systematic Review and Meta-Analysis.

Authors:  Dang Wu; Pin Wu; Lufeng Zhao; Lijian Huang; Zhigang Zhang; Shuai Zhao; Jian Huang
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.